Study Results


People with ROS1+ non-small cell lung cancer can be treated with AUGTYRO as their first targeted therapy.

In a study of 71 people with ROS1+ lung cancer, they were given AUGTYRO as their first targeted therapy. They received AUGTYRO starting at 160 mg orally once daily for 14 days, and then their dose was increased to 160 mg twice daily until their doctor recommended otherwise.

Study-results Study-results

Possible side effects

Possible Side Effects to Look Out For

During treatment with AUGTYRO, side effects may occur. It’s important to be mindful, track changes, and assess how you’re feeling.

Rely on your care team

To have helpful conversations with them, remember to let your team know if you are experiencing any new or different symptoms at any time during your treatment.

AUGTYRO may cause serious side effects, including:

  • Central nervous system (CNS) effects
  • Lung problems (pneumonitis)
  • Liver problems
  • Muscle problems
  • Increased uric acid in your blood (hyperuricemia)
  • Bone fractures

The most common side effects of AUGTYRO include:

  • Dizziness
  • Change in sense of taste
  • Feeling of numbness or tingling in your arms or legs
  • Constipation
  • Trouble with balance, coordination, and walking
  • Shortness of breath
  • Problems with thinking, such as forgetfulness or confusion, memory problems and hallucinations
  • Tiredness
  • Nausea